Atlas Trials

An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients

Clinical trial NCT03897205 · COMPLETED

Trial details

NCT number
NCT03897205
Sponsor
Hansa Biopharma AB
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Kidney Transplant Rejection
Start date
2019-04-30
Primary completion
2022-05-28
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.